FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324136690> ?p ?o ?g. }

• W4324136690 endingPage "107" @default.
• W4324136690 startingPage "107" @default.
• W4324136690 abstract "107 Background: The optimal management of mCRPC in men aged ≥75 is challenging, and there is a paucity of clinical data in the literature. Although AA and E are commonly used as 1 st line Rx for mCRPC, it is unclear whether use of upfront D for mCSPC may impact their clinical efficacy or safety in this elderly population. Methods: Patients aged ≥75 who started AA or E as 1 st line Rx for mCRPC within January 2015 - April 2019 were identified from the IRB approved databases of 10 institutions in Europe, South and North America. Demographic and clinicopathological data were collected from available medical records, including Gleason, prior local therapy, newly diagnosed metastatic disease, disease volume, ECOG, PSA and sites of metastases. Patients were classified by use of upfront D for mCSPC. The primary endpoints were overall survival (OS) from AA/E onset and OS from ADT start and safety of AA/E. The endpoints distributions including median (95% CI) were estimated by Kaplan-Meier method. Results: Of the 337 patients selected, 24 (7.1%) received ADT+D and 313 (92.9%) ADT alone for mCSPC. Patients with ADT+D tended to be younger (78 vs 81, p=0.022) and, albeit not statistically significant, had higher rates of Gleason score >8 (81.0% vs 62.6%, p=0.10), newly diagnosed (83.3% vs 65.6%, p=0.08) and high volume disease (45.8% vs 34.6%, p=0.28), compared to those with ADT alone. Median follow-up was 18.8 months. No significant difference of OS from ADT start or from AA/E onset was observed between the 2 cohorts (see table). Despite OS from ADT start being longer in those having ADT+D, OS from AA/E start was approximately 2 years in both cohorts. Rates of adverse events (AEs) of any grade (58.3% vs 52.1%, p=0.67) and grade ≥3 (12.5% vs 15.7%, p=1.0) did not significantly differ between the 2 cohorts. Conclusions: While limited by small sample size for ADT+D and retrospective study design, patients aged ≥75 having AA/E as 1 st line mCRPC Rx showed similar survival outcomes and tolerability regardless of previous use of D for mCSPC. [Table: see text]" @default.
• W4324136690 created "2023-03-15" @default.
• W4324136690 creator A5009277251 @default.
• W4324136690 creator A5017866134 @default.
• W4324136690 creator A5018153995 @default.
• W4324136690 creator A5032943515 @default.
• W4324136690 creator A5036125918 @default.
• W4324136690 creator A5036946878 @default.
• W4324136690 creator A5037646183 @default.
• W4324136690 creator A5042146146 @default.
• W4324136690 creator A5047133719 @default.
• W4324136690 creator A5053905496 @default.
• W4324136690 creator A5057926104 @default.
• W4324136690 creator A5064026892 @default.
• W4324136690 creator A5071060598 @default.
• W4324136690 creator A5074461929 @default.
• W4324136690 creator A5075586588 @default.
• W4324136690 creator A5078631166 @default.
• W4324136690 creator A5081355165 @default.
• W4324136690 creator A5083659627 @default.
• W4324136690 creator A5086693874 @default.
• W4324136690 creator A5091765229 @default.
• W4324136690 date "2023-02-20" @default.
• W4324136690 modified "2023-09-23" @default.
• W4324136690 title "Clinical outcomes of abiraterone acetate (AA) or enzalutamide (E) as first-line therapy (Rx) for men aged ≥75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC) in a multicenter international registry: A SPARTACUSS – Meet-URO 26 study." @default.
• W4324136690 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.107" @default.
• W4324136690 hasPublicationYear "2023" @default.
• W4324136690 type Work @default.
• W4324136690 citedByCount "0" @default.
• W4324136690 crossrefType "journal-article" @default.
• W4324136690 hasAuthorship W4324136690A5009277251 @default.
• W4324136690 hasAuthorship W4324136690A5017866134 @default.
• W4324136690 hasAuthorship W4324136690A5018153995 @default.
• W4324136690 hasAuthorship W4324136690A5032943515 @default.
• W4324136690 hasAuthorship W4324136690A5036125918 @default.
• W4324136690 hasAuthorship W4324136690A5036946878 @default.
• W4324136690 hasAuthorship W4324136690A5037646183 @default.
• W4324136690 hasAuthorship W4324136690A5042146146 @default.
• W4324136690 hasAuthorship W4324136690A5047133719 @default.
• W4324136690 hasAuthorship W4324136690A5053905496 @default.
• W4324136690 hasAuthorship W4324136690A5057926104 @default.
• W4324136690 hasAuthorship W4324136690A5064026892 @default.
• W4324136690 hasAuthorship W4324136690A5071060598 @default.
• W4324136690 hasAuthorship W4324136690A5074461929 @default.
• W4324136690 hasAuthorship W4324136690A5075586588 @default.
• W4324136690 hasAuthorship W4324136690A5078631166 @default.
• W4324136690 hasAuthorship W4324136690A5081355165 @default.
• W4324136690 hasAuthorship W4324136690A5083659627 @default.
• W4324136690 hasAuthorship W4324136690A5086693874 @default.
• W4324136690 hasAuthorship W4324136690A5091765229 @default.
• W4324136690 hasConcept C121608353 @default.
• W4324136690 hasConcept C126322002 @default.
• W4324136690 hasConcept C143998085 @default.
• W4324136690 hasConcept C203092338 @default.
• W4324136690 hasConcept C2775832370 @default.
• W4324136690 hasConcept C2776421732 @default.
• W4324136690 hasConcept C2776551883 @default.
• W4324136690 hasConcept C2777899217 @default.
• W4324136690 hasConcept C2780192828 @default.
• W4324136690 hasConcept C2781190966 @default.
• W4324136690 hasConcept C2908647359 @default.
• W4324136690 hasConcept C535046627 @default.
• W4324136690 hasConcept C61367390 @default.
• W4324136690 hasConcept C71924100 @default.
• W4324136690 hasConcept C99454951 @default.
• W4324136690 hasConceptScore W4324136690C121608353 @default.
• W4324136690 hasConceptScore W4324136690C126322002 @default.
• W4324136690 hasConceptScore W4324136690C143998085 @default.
• W4324136690 hasConceptScore W4324136690C203092338 @default.
• W4324136690 hasConceptScore W4324136690C2775832370 @default.
• W4324136690 hasConceptScore W4324136690C2776421732 @default.
• W4324136690 hasConceptScore W4324136690C2776551883 @default.
• W4324136690 hasConceptScore W4324136690C2777899217 @default.
• W4324136690 hasConceptScore W4324136690C2780192828 @default.
• W4324136690 hasConceptScore W4324136690C2781190966 @default.
• W4324136690 hasConceptScore W4324136690C2908647359 @default.
• W4324136690 hasConceptScore W4324136690C535046627 @default.
• W4324136690 hasConceptScore W4324136690C61367390 @default.
• W4324136690 hasConceptScore W4324136690C71924100 @default.
• W4324136690 hasConceptScore W4324136690C99454951 @default.
• W4324136690 hasIssue "6_suppl" @default.
• W4324136690 hasLocation W43241366901 @default.
• W4324136690 hasOpenAccess W4324136690 @default.
• W4324136690 hasPrimaryLocation W43241366901 @default.
• W4324136690 hasRelatedWork W122177069 @default.
• W4324136690 hasRelatedWork W2162738516 @default.
• W4324136690 hasRelatedWork W2768013934 @default.
• W4324136690 hasRelatedWork W2768688864 @default.
• W4324136690 hasRelatedWork W2776594178 @default.
• W4324136690 hasRelatedWork W2935114107 @default.
• W4324136690 hasRelatedWork W2982156914 @default.
• W4324136690 hasRelatedWork W3023947295 @default.
• W4324136690 hasRelatedWork W3156855168 @default.
• W4324136690 hasRelatedWork W4226040508 @default.
• W4324136690 hasVolume "41" @default.
• W4324136690 isParatext "false" @default.
• W4324136690 isRetracted "false" @default.
• W4324136690 workType "article" @default.